July 18, 2024

Received orphan-drug designation from the FDA for our lead molecule, ABI-171, in the treatment of idiopathic pulmonary fibrosis (IPF).

​

July 23, 2023

Avanti Biosciences receives an SBIR Phase 1 grant from the NIDDK (1R43DK134232-01A1) for the development of new therapies for the treatment of liver diseases in collaboration with Ohio State University (Professor Richard Bruno)

​

May 5, 2019

Avanti Biosciences has been awarded the second phase of the fast-track SBIR grants from the NIA for its work on Alzheimer's Disease.

​

July 30, 2018

Avanti Biosciences receives an SBIR Phase 1 grant from the NIDDK for the development of new therapies for the treatment of Hyperinsulinemia Hyperammonemia Syndrome in collaboration with the Children's Hospital of Philadelphia (CHOP)

​

May 1, 2018

Avanti Biosciences open new operations in the JLAB San Diego.

​

August 15, 2017

Avanti Biosciences Receives $1.9M SBIR Fast-Track Award to Further Treatment for Alzheimer’s Disease

​

October 8, 2015

Avanti Biosciences approved by the Long Island High Technology Incubator (LIHTI) as part of the Incubator Without Walls Program initiative.